Tracers / [177Lu]Lu-DOTA-AE105
[177Lu]Lu-DOTA-AE105
Also written as [Lu-177]Lu-DOTA-AE105
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated peptide (nonapeptide AE105 targeting uPAR)
- Target / mechanism
- Urokinase-type plasminogen activator receptor (uPAR) PMID 40326657
- Clinical application
- Cancer (various uPAR-expressing cancer types) PMID 40326657
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | HPLC | — | >99% | DOTA-AE105 | 40326657 2025 Mol Pharm The respective amount of peptide (stock solution of 1 mM) and lutetium-177 were added to a 1/5 (v/v) mixture of sodium acetate (0.5 M) and HCl (0.05 M), followed by incubation of the reaction mixture at 95 °C for 10 min |
Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-AE105, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40326657. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40326657: 'DOTA-AE105'.